Characterization of the resistance mechanisms of HL60 leukemia cell derivatives to Apo2L/TRAIL.

被引：0
|
作者：
Cheng, JR [1 ]
Hyladder, BL [1 ]
Baer, MR [1 ]
Repasky, EA [1 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.3412.3412
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3412
引用
收藏
页码：931A / 931A
页数：1
相关论文
共 50 条
  • [11] Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice
    Sedger, LM
    Glaccum, MB
    Schuh, JCL
    Kanaly, ST
    Williamson, E
    Kayagaki, N
    Yun, T
    Smolak, P
    Le, T
    Goodwin, R
    Gliniak, B
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2002, 32 (08) : 2246 - 2254
  • [12] AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L
    Jerzy S. Pieczykolan
    Konrad Kubiński
    Maciej Masłyk
    Sebastian D. Pawlak
    Anna Pieczykolan
    Piotr K. Rózga
    Michał Szymanik
    Marlena Gałązka
    Małgorzata Teska-Kamińska
    Bartłomiej Żerek
    Katarzyna Bukato
    Katarzyna Poleszak
    Albert Jaworski
    Wojciech Strożek
    Robert Świder
    Rafał Zieliński
    Investigational New Drugs, 2014, 32 : 1155 - 1166
  • [13] AD-O53.2-a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L
    Pieczykolan, Jerzy S.
    Kubinski, Konrad
    Maslyk, Maciej
    Pawlak, Sebastian D.
    Pieczykolan, Anna
    Rozga, Piotr K.
    Szymanik, Michal
    Galazka, Marlena
    Teska-Kaminska, Malgorzata
    Zerek, Bartlomiej
    Bukato, Katarzyna
    Poleszak, Katarzyna
    Jaworski, Albert
    Strozek, Wojciech
    Swider, Robert
    Zielinski, Rafal
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1155 - 1166
  • [14] Transport mechanism of anthracycline derivatives human leukemia cell lines: Uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells
    Nagasawa, K
    Natazuka, T
    Chihara, K
    Kitazawa, F
    Tsumura, A
    Takara, K
    Nomiyama, M
    Ohnishi, N
    Yokoyama, T
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (04) : 297 - 304
  • [15] Defining the mechanisms of APO2L/trail-induced apoptosis in authentic multiple myeloma cells
    Koutrouvelis, KC
    Yeh, SL
    Baulch-Brown, C
    Spencer, A
    EXPERIMENTAL HEMATOLOGY, 2004, 32 (07) : 64 - 64
  • [16] Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)
    Singh, Kamini
    Sharma, Arishya
    Mir, Maria C.
    Drazba, Judith A.
    Heston, Warren D.
    Magi-Galluzzi, Cristina
    Hansel, Donna
    Rubin, Brian P.
    Klein, Eric A.
    Almasan, Alexandru
    MOLECULAR CANCER, 2014, 13
  • [17] TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines
    Yoshida, S
    Narita, T
    Koshida, S
    Ohta, S
    Takeuchi, Y
    PEDIATRIC RESEARCH, 2003, 54 (05) : 709 - 717
  • [18] Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma
    Perez, Lia E.
    Parquet, Nancy
    Meads, Mark
    Anasetti, Claudio
    Dalton, William
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (03) : 212 - 222
  • [19] TRAIL/Apo2L Ligands Induce Apoptosis in Malignant Rhabdoid Tumor Cell Lines
    Shinobu Yoshida
    Tsutomu Narita
    Shigeki Koshida
    Shigeru Ohta
    Yoshihiro Takeuchi
    Pediatric Research, 2003, 54 : 709 - 717
  • [20] Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines
    Siervo-Sassi, RR
    Marrangoni, AM
    Feng, X
    Naoumova, N
    Winans, M
    Edwards, RP
    Lokshin, A
    CANCER LETTERS, 2003, 190 (01) : 61 - 72
12345